Ram Yeleswarapu, President and CEO and Subhasri Sriram, Chief Financial Officer of the company addressed the call.

Highlights of the call

The company is a globally recognized domain intensive services provider in Life Sciences.

Take Solutions delivers domain-intensive services in Life Sciences and Supply Chain Management.

In the fast-growing Life Sciences space, it offers clients a unique combination of a full-service CRO backed by industry insights and technology expertise.

Its range of services span from clinical trials to regulatory submissions to post-marketing safety, all backed by insights derived through proprietary industry networks.

In SCM the company focuses on high margin niches in engineering, mobility and collaboration.

The quarter witnessed strong business growth.

Quarter sales grew 10% qoq and 19% yoy to Rs 408.02 crore.

Quarter PAT grew 14% qoq and 11% yoy to Rs 41.96 crore.

Revenue has grown 23% in $ terms during the quarter.

Life sciences revenues grew 25% yoy.

Nine months sales grew 15% to Rs 1133.32 crore.

Nine months PAT grew 10% to Rs 114.37 crore.

In response to emerging opportunities preferential allotment of Rs 250 crore will be made to promoters.

The funds raised will be used to capitalize on growth opportunities and scale business in the clinical and regulatory spaces inorganically through strategic acquisitions in North America and European markets.

Pricing will be made as per SEBI guidelines and the process will start immediately.

During the quarter customer base of small and medium pharma for Pharmeready software crossed 150 and is climbing steadily.

Scales of BA/BE business with 80 bedded Clinical Pharmacology Unit which will be ready to commence operations soon.

The company has aligned all capabilities to digitize R&D of life sciences.

The $ 33 Billion Life Sciences R&D Outsourcing Market is pegged to grow at 7-10% over the next three years. This growth is fueled by biopharma companies looking to stay compliant, control costs, and maintain internal focus on core activities.

The company has worked with over 150 pharmaceutical companies across the globe,

The company delivers outcomes for clients including 9 out of 10 to global pharmaceutical companies.

Rapid growth is expected in biosimilars market due to patents of all of the top 30 biological drugs expiring before 2025.

The company has extensive clinical experience and can monitor and treat potential severe adverse responses to biosimilar drug

Mid-size pharma is seeing lot of traction.

Small and medium companies contribute to 50% of the global R&D spend, especially in novel therapies like monoclonal antibodies and peptides

While the US and EU are leading markets, consumption patterns indicate that the Asian market has enormous growth potential. These growing companies and markets present an attractive growth opportunity.

Besides Oncology, its expertise in Dermatology and Ophthalmology therapeutic areas is garnering a lot of discussions with customers.

Order book stood $ 163.1 million out of $ 151 million is from life Science and $ 12 million is from supply chain domain.

M&A environment continues to be very bullish and active.

Incremental capex was Rs 52.40 crore during the quarter.

Between Q2 and Q3 rupee had depreciated.